Filing Overview
CytoMed Therapeutics Limited filed a Form 6-K dated May 24, 2024, reporting matters from its 2024 annual shareholders meeting held on May 15, 2024. The company is a Singapore-based foreign private issuer that files annual reports on Form 20-F.
Business Context and Reporting Period
The filing concerns corporate governance, financial statement adoption, auditor appointments, director matters, director compensation, and share-issuance authority. It does not provide operating or financial results for a quarterly or annual reporting period.
Of 11,540,000 outstanding ordinary shares, 6,714,256 shares were represented at the meeting, equal to approximately 58.18% and sufficient to constitute a quorum.
Financial and Capital Markets Information
- Revenue, profit, cash flow, margins, cash balance, debt, liquidity, and other operating metrics were not reported in the filing.
- Shareholders approved directors’ fees of US$90,000 for the year ending December 31, 2024.
- Shareholders approved directors’ fees of US$70,000 for the year ended December 31, 2023.
- The directors were authorized to issue ordinary shares and securities convertible into ordinary shares, subject to applicable Singapore law, Nasdaq rules, and the company’s constitution.
- The authorization generally continues until the next annual general meeting or the legally required date for that meeting, unless earlier revoked or varied.
Material Changes and Meeting Results
- All eight proposals were approved as recommended by the board.
- Shareholders adopted the directors’ statement and the audited financial statements related to the December 31, 2023 fiscal year and Form 20-F.
- Choo Chee Kong was re-elected as a director.
- Wu Tao Thomas and Dr. Lucas Luk Tien Wee resigned as directors and did not stand for re-election.
- WWC, P.C. was ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- KE Trust PAC was also ratified as the independent registered public accounting firm for the year ending December 31, 2024.
- The meeting-adjournment proposal was approved, although the filing indicates that all submitted proposals were approved and does not indicate that an adjournment was required.
Voting Summary
| Proposal | For | Against | Abstentions/Withheld | Broker non-votes |
|---|---|---|---|---|
| 1. Adopt directors’ statement | 6,714,126 | 130 | 0 | 0 |
| 2. Adopt audited financial statements related to Form 20-F | 6,714,126 | 130 | 0 | 0 |
| 3. Re-elect Choo Chee Kong | 6,714,126 | 130 | 0 | 0 |
| 4. Ratify WWC, P.C. | 6,714,126 | 130 | 0 | 0 |
| 5. Ratify KE Trust PAC | 6,713,972 | 284 | 0 | 0 |
| 6. Approve directors’ fees | 6,714,078 | 178 | 0 | 0 |
| 7. Authorize adjournment if necessary | 6,714,078 | 178 | 0 | 0 |
| 8. Authorize issuance of ordinary shares | 6,714,078 | 178 | 0 | 0 |
Guidance, Outlook, Risks, and Unusual Items
- No revenue, earnings, operational guidance, or forward-looking outlook was provided.
- The share-issuance authorization creates potential future dilution and permits issuance of shares or convertible instruments for purposes including the company’s Nasdaq listing and other uses determined by the board, subject to applicable requirements.
- The filing does not identify material litigation, contingencies, debt developments, liquidity concerns, or unusual financial items.
- The departure of two directors represents a board-composition change; the filing does not provide reasons or additional succession details.
Investor Verification Items
- Verify the December 31, 2023 audited financial statements and the related Form 20-F for actual revenue, losses, cash resources, debt, liquidity, and going-concern disclosures.
- Review the scope and terms of the authorization to issue ordinary shares, options, warrants, debentures, or other convertible instruments, including potential dilution.
- Confirm the current board composition following the resignations of Wu Tao Thomas and Dr. Lucas Luk Tien Wee and the re-election of Choo Chee Kong.
- Review the independence, appointment terms, and remuneration arrangements for WWC, P.C. and KE Trust PAC.
- Determine whether the authorized share issuance has subsequently been used or modified in later filings.